MDT

98.76

+1.94%↑

A

146.17

-0.01%↓

VEEV

219.86

-1.14%↓

HQY

89.05

+3.23%↑

NEOG

9.5

+3.26%↑

MDT

98.76

+1.94%↑

A

146.17

-0.01%↓

VEEV

219.86

-1.14%↓

HQY

89.05

+3.23%↑

NEOG

9.5

+3.26%↑

MDT

98.76

+1.94%↑

A

146.17

-0.01%↓

VEEV

219.86

-1.14%↓

HQY

89.05

+3.23%↑

NEOG

9.5

+3.26%↑

MDT

98.76

+1.94%↑

A

146.17

-0.01%↓

VEEV

219.86

-1.14%↓

HQY

89.05

+3.23%↑

NEOG

9.5

+3.26%↑

MDT

98.76

+1.94%↑

A

146.17

-0.01%↓

VEEV

219.86

-1.14%↓

HQY

89.05

+3.23%↑

NEOG

9.5

+3.26%↑

Search

Quidel Corp

Aperta

34.91 4.74

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

33.23

Massimo

35.05

Metriche Chiave

By Trading Economics

Dipendenti

6,600

Raccomandazioni

By TipRanks

Raccomandazioni

Neutrale

Previsioni per 12 mesi

-20.42% downside

Dividendi

By Dow Jones

Utili prossimi

11 feb 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

305M

1.9B

Apertura precedente

30.17

Chiusura precedente

34.91

Quidel Corp Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

14 gen 2026, 22:41 UTC

Acquisizioni, Fusioni, Takeovers

Canadian Natural Resources, Tourmaline File Deal Notice With Antitrust Regulator

15 gen 2026, 00:00 UTC

Utili

Welcome to Greenland, an Economy Reliant on Subsidies and Shrimp -- WSJ

14 gen 2026, 23:47 UTC

Discorsi di Mercato

Oil Slips After Trump Appears to Tilt Away From Military Action in Iran -- Market Talk

14 gen 2026, 23:44 UTC

Discorsi di Mercato

Nikkei May Decline After Hitting Record Highs; Election in Focus -- Market Talk

14 gen 2026, 23:39 UTC

Discorsi di Mercato

ANZ's New Bull Still Sees Valuation Gap to Peers -- Market Talk

14 gen 2026, 23:32 UTC

Discorsi di Mercato

Gold Declines on Likely Technical Correction, Possible Profit-Taking -- Market Talk

14 gen 2026, 22:56 UTC

Acquisizioni, Fusioni, Takeovers

Soho House Amends Rollover and Support Agreements With Broad Street Principal Investments and Others

14 gen 2026, 22:53 UTC

Acquisizioni, Fusioni, Takeovers

Soho House: Apollo Global Management and Goldman Sachs Asset Management Amend Debt Commitment

14 gen 2026, 22:17 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

14 gen 2026, 22:17 UTC

Discorsi di Mercato

WiseTech's Revenue Growth Drivers Attract Scrutiny -- Market Talk

14 gen 2026, 22:09 UTC

Utili

CITIC Securities: Uptrend in China Capital Markets Supported Results >600030.SH

14 gen 2026, 22:08 UTC

Utili

CITIC Securities 2025 Oper Rev CNY74.83B Vs. CNY58.12B >600030.SH

14 gen 2026, 22:08 UTC

Utili

CITIC Securities 2025 Net CNY30.05B Vs. Net CNY21.57B >600030.SH

14 gen 2026, 21:53 UTC

Acquisizioni, Fusioni, Takeovers

WuXi XDC Expects 2025 Net to Increase Over 38% on Year

14 gen 2026, 21:53 UTC

Acquisizioni, Fusioni, Takeovers

WuXi XDC Expects 2025 Revenue to Increase More Than 45% on Year

14 gen 2026, 21:52 UTC

Acquisizioni, Fusioni, Takeovers

WuXi XDC Announces Positive Profit Alert for 2025

14 gen 2026, 21:51 UTC

Acquisizioni, Fusioni, Takeovers

Citigroup Acting as Financial Advisor to WuXi XDC

14 gen 2026, 21:51 UTC

Acquisizioni, Fusioni, Takeovers

WuXi XDC: Aims to Keep Listing Status of BioDlink

14 gen 2026, 21:51 UTC

Acquisizioni, Fusioni, Takeovers

WuXi XDC: Company to Finance BioDlink Shares Acquisition via Internal Resources

14 gen 2026, 21:50 UTC

Discorsi di Mercato
Utili

Financial Services Roundup: Market Talk

14 gen 2026, 21:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

14 gen 2026, 21:49 UTC

Acquisizioni, Fusioni, Takeovers

WuXi XDC: BioDlink Offer to Cost HK$2.79B

14 gen 2026, 21:48 UTC

Acquisizioni, Fusioni, Takeovers

WuXi XDC Offers to Pay HK$4.00 for Each BioDlink International Share

14 gen 2026, 21:48 UTC

Acquisizioni, Fusioni, Takeovers

WuXi XDC Makes Cash Offer for BioDlink International

14 gen 2026, 21:13 UTC

Discorsi di Mercato

Oil Retreats Late After Trump Comments on Iran -- Market Talk

14 gen 2026, 20:30 UTC

Discorsi di Mercato
Utili

Danaher's Preliminary 4Q Seen as Promising -- Market Talk

14 gen 2026, 20:13 UTC

Discorsi di Mercato

U.S. Natural Gas Futures Sink Ahead of Storage Report -- Market Talk

14 gen 2026, 20:08 UTC

Discorsi di Mercato

Oil Futures Extend Rally on Iran Tensions -- Market Talk

14 gen 2026, 19:33 UTC

Discorsi di Mercato

Nutrien Seen as Winner in Tighter 2026 Potash Market, Higher Prices -- Market Talk

14 gen 2026, 19:06 UTC

Discorsi di Mercato
Utili

Wells Fargo Says Customers, Economy Remain Resilient -- Market Talk

Confronto tra pari

Modifica del prezzo

Quidel Corp Previsione

Obiettivo di Prezzo

By TipRanks

-20.42% in calo

Previsioni per 12 mesi

Media 26.5 USD  -20.42%

Alto 31 USD

Basso 22 USD

Basato su 5 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Quidel Corp - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Neutrale

5 ratings

1

Acquista

3

Mantieni

1

Vendi

Notizie finanziarie

$

Chi Siamo Quidel Corp

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides instruments and tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was incorporated in 1979 and is headquartered in San Diego, California.
help-icon Live chat